title: CRIM-negative infantile Pompe disease: 42-month treatment outcome.
abstract: Pompe disease is a rare lysosomal glycogen storage disorder characterized by deficiency of acid α-glucosidase enzyme (GAA) and caused by mutations in the GAA gene. Infantile-type Pompe disease is a multiorgan disorder presenting with cardiomyopathy, hypotonia, and muscular weakness, which is usually fatal. Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) has recently been shown to be effective and subsequently yielded promising results in cross-reactive immunologic material (CRIM)-positive patients. CRIM-negative patients showed a limited response to ERT and died or were ventilator dependant. Over a period of 44 months, we monitored cognitive and motor development, behavior, auditory function, and brain imaging of a CRIM-negative infantile Pompe disease patient on rhGAA and monoclonal anti-immunoglobulin E (anti-IgE) antibody (omalizumab) treatment due to severe allergic reaction. Cardiorespiratory and skeletal muscle response was significant, with almost normal motor development. Cognitive development-in particular, speech and language-deviated increasingly from normal age-appropriate development and was markedly delayed at 44 months, unexplained by moderate sensorineural hearing impairment. Brain magnetic resonance imaging (MRI) at 18, 30, and 44 months of age revealed symmetrical signal alteration of the deep white matter. Titer values of IgG antibodies to rhGAA always remained <1:800. The potential role of omalizumab in immune modulation remains to be elucidated; however, this is the first report presenting a ventilator-free survival of a CRIM-negative patient beyond the age of 36 months. The central nervous system (CNS) findings are hypothesized to be part of a yet not fully described CNS phenotype in treated patients with longer survival.
authors.affiliation: Division of Metabolism, University Children's Hospital Zürich, Steinwiesstrasse 75, 8032 Zürich, Switzerland. Marianne.rohrbach@kispi.uzh.ch
authors.forename: Marianne
authors.initials: M
authors.lastname: Rohrbach
authors.forename: Andrea
authors.initials: A
authors.lastname: Klein
authors.forename: Alice
authors.initials: A
authors.lastname: Köhli-Wiesner
authors.forename: Dorothe
authors.initials: D
authors.lastname: Veraguth
authors.forename: Ianina
authors.initials: I
authors.lastname: Scheer
authors.forename: Christian
authors.initials: C
authors.lastname: Balmer
authors.forename: Roger
authors.initials: R
authors.lastname: Lauener
authors.forename: Matthias R
authors.initials: MR
authors.lastname: Baumgartner
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D002675:Child, Preschool; D003429:Cross Reactions / Q000276:immunology; D056947:Enzyme Replacement Therapy; D005500:Follow-Up Studies; D006009:Glycogen Storage Disease Type II / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D013997:Time Factors; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000627:therapeutic use*
chemical_list: D000888:Antibodies, Anti-Idiotypic; C026408:anti-IgE antibodies; D000520:alpha-Glucosidases